Results 31 to 40 of about 4,101 (234)

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. [PDF]

Blood Adv
Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL.   +30 more
europepmc   +3 more sources

IL-4, IgM, and resistance to BTKi and PI3Kδi in CLL [PDF]

Blood, 2016
In this issue of Blood , [Aguilar-Hernandez et al][1][1][2] refine our understanding of the mechanism of action of interleukin 4 (IL-4) in promoting B-cell receptor (BCR)-mediated signaling in primary human chronic lymphocytic leukemia (CLL) and resistance to a Bruton tyrosine kinase inhibitor ...
Simon D. Wagner
openalex   +3 more sources

Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview. [PDF]

Cancers (Basel)
Dimou M, Fioretzaki R, Zerzi C, Konstantinou E, Asimakopoulos JV, Arapaki M, Piperidou A, Machairas A, Kopsaftopoulou A, Liaskas A, Bitsani A, Belia M, Panitsas F, Benekou A, Petsa P, Plata E, Tsaftaridis P, Siakantaris M, Vassilakopoulos TP, Panayiotidis P, Angelopoulou MK.   +20 more
europepmc   +3 more sources

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL [PDF]

International Journal of Molecular Sciences, 2019
B-cell receptor (BCR) signaling and tumor–microenvironment crosstalk both drive chronic lymphocytic leukemia (CLL) pathogenesis. Within the microenvironment, tumor cells shape the T-cell compartment, which in turn supports tumor growth and survival. Targeting BCR signaling using Bruton tyrosine kinase inhibitors (BTKi) has become a highly successful ...
Maissa Mhibik, Adrian Wiestner, Clare Sun   +2 more
openalex   +4 more sources

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

Frontiers in Immunology, 2023
IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Yuting Yan, Yuting Yan, Rui Lv, Rui Lv, Tingyu Wang, Tingyu Wang, Ying Yu, Ying Yu, Yanshan Huang, Yanshan Huang, Wenjie Xiong, Wenjie Xiong, Yuxi Li, Yuxi Li, Weiwei Sui, Weiwei Sui, Qi Wang, Qi Wang, Wenyang Huang, Wenyang Huang, Gang An, Gang An, Dehui Zou, Dehui Zou, Jianxiang Wang, Jianxiang Wang, Lugui Qiu, Lugui Qiu, Shuhua Yi, Shuhua Yi   +29 more
doaj   +1 more source

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence

Journal of Translational Medicine, 2021
Background The development of Bruton’s tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy.
Joanne E. Davis, Chia Sharpe, Kylie Mason, Constantine S. Tam, Rachel M. Koldej, David S. Ritchie   +5 more
doaj   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Abstract Background Real‐world data are an essential complement to clinical trials. This is particularly true for chronic lymphocytic leukemia, where five first‐line options have never been directly compared. Methods The authors present the results of a national multicenter real‐world study focusing on treatment choices in frontline chronic lymphocytic
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +2 more sources

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

HemaSphere, 2023
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Marina Motta, Marina Deodato, Elisa Bossi, Veronica Mattiello, Maria Beatrice Ferrari, Giulia Cotilli, Carlo Gambacorti‐Passerini, Roberto Cairoli, Massimo Puoti, Alessandra Tedeschi   +14 more
openalex   +4 more sources

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis

Scientific Reports, 2023
The efficacy of Bruton tyrosine kinase inhibitors (BTKi) remains suboptimal in chronic lymphocytic leukemia (CLL) treatment. A systematic review and meta-analysis were conducted to compare the outcomes of combining anti-CD20 monoclonal antibodies (mAb ...
Thi Thuy Nguyen, Nguyen Thanh Nhu, Van Khoi Tran, Nguyen-Kieu Viet-Nhi, Xuan Dung Ho, Ming-Kai Jhan, Ya-Ping Chen, Chiou-Feng Lin   +7 more
doaj   +1 more source

STRATEGI PENINGKATAN EKSPOR DENGAN MEMAKSIMALKAN INTELIJEN BISNIS DAN UTILISASI FORMAT BUKU TARIP KEPABEANAN INDONESIA (BTKI) [PDF]

PROSEDING SEMINAR NASIONAL AKUNTANSI, 2018
Increased export volume is always pursued by countries in the world. Increased export opportunities required optimal effort and efficient through Business Intelligence is an activity the ability to understand and understand a reciprocal relationship ...
Firdiansyah, Akhmad
core   +3 more sources